Regression of Follicular Lymphoma of the Duodenum Following Eradication of &lt;i&gt;H. pylori&lt;/i&gt; Infection

Hayashi, Hiroki; Onishi, Yutaka; Mitsuoka, Hiroshi; Ogura, Takeshi; Maeda, Mitsuo; Nishigami, Takashi; Harada, Masaru

doi:10.2169/internalmedicine.52.0552

Cited by 11 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although Helicobacter pylori (HP) eradication is sometimes chosen for patients with infection, eradication does not have any therapeutic effect in most cases. There are four case reports that show an FL lesion was regressed by HP eradication and one case in our 125 cases of this multicenter retrospective cohort, but whole GI tract examination was not performed in those cases . Hence, it is doubtful at this time whether HP is associated with GI‐FL pathogenesis.…”

Section: Clinical Characteristics Of Gi‐flmentioning

confidence: 89%

“…There are four case reports that show an FL lesion was regressed by HP eradication and one case in our 125 cases of this multicenter retrospective cohort, but whole GI tract examination was not performed in those cases. 8,[21][22][23][24] Hence, it is doubtful at this time whether HP is associated with GI-FL pathogenesis.…”

Section: Clinical Characteristics Of Gi-flmentioning

confidence: 99%

See 1 more Smart Citation

Gastrointestinal follicular lymphoma: Current knowledge and future challenges

Takata

Miyata‐Takata

Sato

et al. 2018

Pathology International

View full text Add to dashboard Cite

The gastrointestinal (GI) tract is the most commonly involved site of extranodal follicular lymphoma (FL). GI-FL shows very indolent clinical behavior and localized at GI tract without any progression or transformation compared to nodal FL. The most frequently involved site of the GI tract was the duodenum followed by the jejunum and ileum, and only 15% of FL arising in the second part of the duodenum were localized there without scattered very small daughter lesions in other GI tract examined by double-balloon endoscopy. The typical macroscopic appearance of GI-FL was multiple white nodules. Microscopically, neoplastic cells were small-to medium-sized lymphoid cells and formed neoplastic follicles. Most of the cases (>95%) were histologically Grade 1 to 2 (low grade). Several pathological and molecular characteristics were seen in GI-FL (especially duodenal FL) compared with nodal FL: immunoglobulin heavy chain deviation to VH4 and VH5; memory B-cell immunophenotype; and molecular features shared by mucosa-associated lymphoid tissue lymphoma. Considering the pathological and molecular uniqueness of this disease, GI-FL should be separately managed from nodal FL.

show abstract

Section: Clinical Characteristics Of Gi‐flmentioning

confidence: 89%

Section: Clinical Characteristics Of Gi-flmentioning

confidence: 99%

Gastrointestinal follicular lymphoma: Current knowledge and future challenges

Takata

Miyata‐Takata

Sato

et al. 2018

Pathology International

View full text Add to dashboard Cite

show abstract

“…Despite the good prognosis associated with DFL, some cases can develop histologic transformation (HT) to aggressive lymphoma, mainly diffuse large B cell lymphoma (DLBCL) (Akiyama et al, 2014;Miyata-Takata et al, 2014). The relation of DFL to helicobacter pylori infection, considering the possible pathologic similarities with MALT lymphoma, has motivated treatment with antibiotics but with mixed results (Yaguchi et al, 2010;Hayashi et al, 2013). There are little data on that subject, although Schmatz et al (2011) did not find any effectiveness.…”

Section: Treatmentmentioning

confidence: 99%

What do we know about duodenal‐type follicular lymphoma? From pathological definition to treatment options

2019

View full text Add to dashboard Cite

Summary Duodenal‐type follicular lymphoma (DFL) is a newly recognised variant of follicular lymphoma (FL), although little is known about its biology and clinical evolution. In general, patients tend to have mild symptoms and do not require therapy, comparable with other forms of low‐tumour burden asymptomatic FL. Specific pathological features, such as a dendritic cell meshwork, low expression of CD10 and upregulation of activation‐induced cytidine deaminase can help the diagnosis. The molecular landscape of DFL is similar to the classical nodal presentation of FL, although studies using gene expression profiling demonstrate a close relation with MALT lymphomas. Markers associated with inflammation have suggested that the microenvironment plays a likely role in the pathogenesis of DFL and its low progression rate. Clinical series published vary between 20–63 patients with an estimated overall survival between 92–100% and a median follow‐up ranging between 20 and 107 months. Treatment options include a watch and wait strategy, rituximab monotherapy and radiotherapy. In this review, we summarise current pathological data and treatment studies in DFL.

show abstract

“…Because H pylori is involved in gastric MALT development, we hypothesized that an exogenous infectious agent may be associated with GI‐FL. The efficacy of antimicrobial therapy for GI‐FL has been demonstrated in both H pylori ‐positive and H pylori ‐negative cases, , suggesting that gastrointestinal bacteria other than H pylori might be involved in the GI‐FL pathogenesis. Although identifying the gastrointestinal bacteria involved in GI‐FL development is expected to help elucidate the pathogenic mechanisms of GI‐FL and establish new treatment strategies, the GI‐FL microbiota has rarely been analyzed to date.…”

Section: Introductionmentioning

confidence: 99%

“…2 Because H pylori is involved in gastric MALT development, we hypothesized that an exogenous infectious agent may be associated with GI-FL. The efficacy of antimicrobial therapy for GI-FL has been demonstrated in both H pylori-positive 11 and H pylori-negative cases, 12,13 suggesting that gastrointestinal bacteria other than H pylori might be involved in the GI-FL pathogenesis.…”

Section: Introductionmentioning

confidence: 99%

Mucosal dysbiosis in patients with gastrointestinal follicular lymphoma

Zeze

Hirano

Torisu

et al. 2020

Hematological Oncology

View full text Add to dashboard Cite

Because the pathogenesis of gastrointestinal follicular lymphoma (GI‐FL) remains unclear, no standardized treatment strategy has been established. Of the gastrointestinal lymphomas, gastric mucosa‐associated lymphoid tissue lymphomas are strongly associated with Helicobacter pylori; hence, the microbiota may be involved in GI‐FL pathogenesis. However, the association between GI‐FL and the microbiota remains uninvestigated. Therefore, we compared the mucosal microbiotas of GI‐FL patients with those of controls to identify microbiota changes in GI‐FL patients. Mucosal biopsy samples were obtained from the second portion of the duodenum from 20 GI‐FL patients with duodenal lesions and 20 controls. Subsequent 16S rRNA gene sequencing was performed on these samples. QIIME pipeline and LEfSe software were used to analyze the microbiota. The GI‐FL patients had significantly lower alpha diversity (P = .049) than did the controls, with significant differences in the microbial composition (P = .023) evaluated by the beta diversity metrics between the two groups. Comparing the taxonomic compositions indicated that the genera Sporomusa, Rothia, and Prevotella and the family Gemellaceae were significantly less abundant in the GI‐FL patients than in the controls. GI‐FL patients presented altered duodenal mucosal microbial compositions, suggesting that the microbiota might be involved in the GI‐FL pathogenesis.

show abstract

Regression of Follicular Lymphoma of the Duodenum Following Eradication of <i>H. pylori</i> Infection

Cited by 11 publications

References 20 publications

Gastrointestinal follicular lymphoma: Current knowledge and future challenges

Gastrointestinal follicular lymphoma: Current knowledge and future challenges

What do we know about duodenal‐type follicular lymphoma? From pathological definition to treatment options

Mucosal dysbiosis in patients with gastrointestinal follicular lymphoma

Contact Info

Product

Resources

About